RenaissanceRe (RNR)
NYSEFinancialsInsurance - ReinsuranceSnapshot 2026-09-14
$330.62+1.73%
Close 2026-09-14 · 1-day change
NYSEFinancialsInsurance - ReinsuranceSnapshot 2026-09-14
Research Workspace
Put RNR beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Financials is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — EPS at least $6.57 in FY 2026: EPS guidance $6.57 vs target $6.57.
View ThesisRevenue is contracting — down about 14% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 9%.
View QualityManagement screens strong on capital allocation, the balance sheet.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskRenaissanceRe's growth has to keep compounding to justify the price. Revenue growth has been steady, with the latest earnings beat showing an EPS of 12.92, exceeding expectations by 12.9%. It trades at 1.1× price-to-book, below the 1.3× peer median, indicating that the price reflects less growth than forecasted. The primary risk is the potential for a guidance cut, with a 17% probability of missing outlook. Peer multiples imply a price about 48% above where it trades. Our read remains provisional.
Trailing returns as of 2026-09-14. RNR is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 17 analysts currently covering RNR (as of Sep 2026).
Based on 6 Wall Street analysts offering 12-month price targets for RNR in the last 4 months.
Continue this research
Compare RNR with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| RNR Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 10 valuation methods, at three horizons. As of 2026-09-14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Financials (broad) — fair value, gap to price, and forward P/E.
Compare the value case
Put RNR next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Drive strong underwriting performance with disciplined portfolio management
Positive outlook supports strong underwriting performance.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-14. EPS is implied from price ÷ P/E. Not investment advice.
Current $330.62
The last 12 months of price, then the range of analyst 12-month targets from today’s $330.62.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Focus on profitability improvement
Strong operating income supports profitability improvement objective.
Advances: Enhance cash flow from operations
Anticipated management fees enhance cash flow from operations.
Threatens: Focus on profitability improvement
Softening reinsurance pricing may impact profitability.
Leadership changes may impact strategic execution and profitability.
Advances: Maintain dividend stability
Dividend declaration supports cash flow stability.
Advances: Focus on profitability improvement
Earnings beat indicates strong profitability improvement.
